Zaloguj Zarejestruj się zadarmo

Acelrx Pharmaceuticals Inc organizacji EPS Q/Q

Jaka jest wartość EPS Q/Q organizacji Acelrx Pharmaceuticals Inc?

Wartość EPS Q/Q organizacji Acelrx Pharmaceuticals Inc to -12,100.00%

Jaka jest definicja EPS Q/Q?



Perspektywiczna kwartalna stopa wzrostu (Quarterly EPS growth rate) to szacowany wzrost wartości EPS w ujęciu kwartalnym za ostatnie cztery kwartały w porównaniu z wynikami z ostatnich czterech kwartałów.

The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

EPS Q/Q firm w Health Care sektor na NASDAQ w porównaniu do Acelrx Pharmaceuticals Inc

Czym się zajmuję organizacja Acelrx Pharmaceuticals Inc?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Firmy z eps q/q podobne do Acelrx Pharmaceuticals Inc